| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 56 | 2024 | 158 | 13.420 |
Why?
|
| Heart Failure | 79 | 2025 | 965 | 12.090 |
Why?
|
| Heart Transplantation | 16 | 2024 | 180 | 3.970 |
Why?
|
| Ventricular Dysfunction, Right | 10 | 2022 | 50 | 3.490 |
Why?
|
| Thrombosis | 7 | 2020 | 207 | 1.830 |
Why?
|
| Heart Ventricles | 8 | 2025 | 267 | 1.690 |
Why?
|
| Stroke Volume | 10 | 2025 | 345 | 1.670 |
Why?
|
| Ventricular Function, Left | 8 | 2025 | 284 | 1.640 |
Why?
|
| Treatment Outcome | 37 | 2024 | 5820 | 1.330 |
Why?
|
| Hypertension, Pulmonary | 3 | 2022 | 100 | 1.310 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2022 | 63 | 1.270 |
Why?
|
| Glomerular Filtration Rate | 4 | 2025 | 121 | 1.140 |
Why?
|
| Vascular Resistance | 2 | 2024 | 47 | 1.020 |
Why?
|
| Registries | 9 | 2024 | 934 | 1.000 |
Why?
|
| Hemodynamics | 11 | 2022 | 252 | 0.980 |
Why?
|
| Humans | 100 | 2025 | 65654 | 0.970 |
Why?
|
| Retrospective Studies | 29 | 2025 | 6948 | 0.930 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 3 | 2024 | 15 | 0.930 |
Why?
|
| Losartan | 4 | 2023 | 19 | 0.920 |
Why?
|
| Ventricular Remodeling | 2 | 2025 | 95 | 0.910 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2019 | 170 | 0.900 |
Why?
|
| Preoperative Care | 3 | 2016 | 199 | 0.860 |
Why?
|
| Middle Aged | 51 | 2025 | 18440 | 0.840 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2022 | 139 | 0.730 |
Why?
|
| Stroke | 3 | 2022 | 1221 | 0.690 |
Why?
|
| Male | 53 | 2025 | 31297 | 0.680 |
Why?
|
| Aged | 34 | 2025 | 15090 | 0.640 |
Why?
|
| Ventricular Function, Right | 4 | 2022 | 28 | 0.630 |
Why?
|
| Shock, Cardiogenic | 4 | 2018 | 108 | 0.610 |
Why?
|
| Hospitalization | 3 | 2023 | 1403 | 0.600 |
Why?
|
| Spironolactone | 2 | 2024 | 9 | 0.590 |
Why?
|
| Female | 49 | 2025 | 34310 | 0.590 |
Why?
|
| Kidney | 4 | 2025 | 458 | 0.560 |
Why?
|
| Obesity, Morbid | 1 | 2019 | 94 | 0.550 |
Why?
|
| Furosemide | 1 | 2018 | 19 | 0.540 |
Why?
|
| Peptide Fragments | 3 | 2022 | 418 | 0.540 |
Why?
|
| Adult | 31 | 2024 | 17511 | 0.520 |
Why?
|
| Quality of Life | 5 | 2023 | 1265 | 0.520 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2014 | 45 | 0.510 |
Why?
|
| Diuretics | 4 | 2024 | 58 | 0.510 |
Why?
|
| Prosthesis Implantation | 3 | 2021 | 30 | 0.490 |
Why?
|
| Body Mass Index | 2 | 2019 | 900 | 0.470 |
Why?
|
| Prospective Studies | 13 | 2025 | 3329 | 0.470 |
Why?
|
| Follow-Up Studies | 13 | 2024 | 2496 | 0.460 |
Why?
|
| Risk Factors | 14 | 2025 | 5466 | 0.450 |
Why?
|
| Biomarkers | 7 | 2025 | 1487 | 0.450 |
Why?
|
| Cause of Death | 1 | 2016 | 221 | 0.430 |
Why?
|
| Patient Care Planning | 1 | 2015 | 85 | 0.430 |
Why?
|
| Antithrombins | 1 | 2014 | 16 | 0.430 |
Why?
|
| Acute Disease | 7 | 2025 | 663 | 0.420 |
Why?
|
| Patients | 1 | 2015 | 117 | 0.410 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 272 | 0.400 |
Why?
|
| Prognosis | 6 | 2025 | 1791 | 0.400 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2012 | 23 | 0.380 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2015 | 142 | 0.380 |
Why?
|
| Graft Rejection | 4 | 2019 | 304 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2024 | 858 | 0.360 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2024 | 66 | 0.360 |
Why?
|
| Patient Care Team | 1 | 2015 | 337 | 0.360 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 142 | 0.350 |
Why?
|
| Caregivers | 1 | 2015 | 298 | 0.350 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 2 | 2022 | 6 | 0.340 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2022 | 6 | 0.340 |
Why?
|
| Survival Rate | 9 | 2019 | 847 | 0.320 |
Why?
|
| Fibrinolytic Agents | 2 | 2014 | 183 | 0.320 |
Why?
|
| Pulmonary Artery | 3 | 2022 | 96 | 0.320 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2011 | 126 | 0.310 |
Why?
|
| American Heart Association | 4 | 2017 | 128 | 0.290 |
Why?
|
| Survival Analysis | 3 | 2021 | 579 | 0.290 |
Why?
|
| Tachycardia, Ventricular | 2 | 2023 | 131 | 0.290 |
Why?
|
| Defibrillators, Implantable | 3 | 2023 | 273 | 0.280 |
Why?
|
| Hemolysis | 2 | 2018 | 41 | 0.260 |
Why?
|
| Potassium | 2 | 2024 | 98 | 0.250 |
Why?
|
| Device Removal | 2 | 2019 | 64 | 0.250 |
Why?
|
| Myocardial Infarction | 2 | 2013 | 921 | 0.250 |
Why?
|
| Intra-Aortic Balloon Pumping | 3 | 2017 | 19 | 0.250 |
Why?
|
| Electrocardiography | 4 | 2024 | 555 | 0.240 |
Why?
|
| Cardiac Catheterization | 4 | 2022 | 293 | 0.240 |
Why?
|
| Pulmonary Wedge Pressure | 4 | 2025 | 28 | 0.240 |
Why?
|
| Tissue Donors | 2 | 2024 | 147 | 0.240 |
Why?
|
| Time Factors | 7 | 2023 | 3777 | 0.240 |
Why?
|
| Cardiac Catheters | 2 | 2016 | 13 | 0.230 |
Why?
|
| Hemoglobins | 2 | 2018 | 136 | 0.230 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 462 | 0.230 |
Why?
|
| Prosthesis Design | 4 | 2015 | 222 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 420 | 0.230 |
Why?
|
| United States | 11 | 2021 | 8166 | 0.220 |
Why?
|
| Postoperative Complications | 3 | 2024 | 1335 | 0.210 |
Why?
|
| Anticoagulants | 4 | 2016 | 529 | 0.200 |
Why?
|
| Hyperuricemia | 1 | 2023 | 7 | 0.200 |
Why?
|
| International Normalized Ratio | 2 | 2015 | 36 | 0.190 |
Why?
|
| Double-Blind Method | 4 | 2024 | 745 | 0.190 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 5657 | 0.190 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2022 | 58 | 0.190 |
Why?
|
| Malnutrition | 1 | 2023 | 41 | 0.190 |
Why?
|
| Aortic Valve | 1 | 2024 | 181 | 0.190 |
Why?
|
| Hypokalemia | 1 | 2022 | 13 | 0.190 |
Why?
|
| Hyperkalemia | 1 | 2022 | 20 | 0.190 |
Why?
|
| Clinical Deterioration | 1 | 2022 | 4 | 0.180 |
Why?
|
| Overweight | 2 | 2017 | 254 | 0.180 |
Why?
|
| Heart Failure, Systolic | 1 | 2022 | 16 | 0.180 |
Why?
|
| Vena Cava, Superior | 1 | 2022 | 9 | 0.180 |
Why?
|
| Aminobutyrates | 1 | 2022 | 9 | 0.180 |
Why?
|
| Valsartan | 1 | 2022 | 12 | 0.180 |
Why?
|
| Disease Management | 3 | 2023 | 235 | 0.180 |
Why?
|
| Waiting Lists | 2 | 2022 | 55 | 0.180 |
Why?
|
| Heart | 1 | 2024 | 298 | 0.180 |
Why?
|
| Biphenyl Compounds | 1 | 2022 | 30 | 0.180 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 22 | 0.170 |
Why?
|
| Incidence | 4 | 2021 | 1432 | 0.170 |
Why?
|
| Homeostasis | 1 | 2024 | 383 | 0.170 |
Why?
|
| Heart Atria | 1 | 2022 | 137 | 0.170 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2018 | 12 | 0.170 |
Why?
|
| Cohort Studies | 5 | 2019 | 2639 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2016 | 2113 | 0.160 |
Why?
|
| Research Personnel | 1 | 2021 | 82 | 0.160 |
Why?
|
| Propensity Score | 1 | 2021 | 192 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2018 | 92 | 0.160 |
Why?
|
| Stents | 1 | 2024 | 501 | 0.160 |
Why?
|
| Patient Readmission | 3 | 2019 | 452 | 0.160 |
Why?
|
| Atrial Pressure | 1 | 2020 | 6 | 0.160 |
Why?
|
| Mental Health | 1 | 2023 | 364 | 0.150 |
Why?
|
| Minority Groups | 1 | 2021 | 143 | 0.150 |
Why?
|
| Thoracic Surgery | 1 | 2021 | 80 | 0.150 |
Why?
|
| Bandages | 1 | 2019 | 17 | 0.150 |
Why?
|
| Research Report | 1 | 2019 | 26 | 0.150 |
Why?
|
| Isoantibodies | 2 | 2019 | 35 | 0.150 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 21 | 0.150 |
Why?
|
| Endoglin | 2 | 2016 | 10 | 0.140 |
Why?
|
| Leadership | 1 | 2021 | 214 | 0.140 |
Why?
|
| Acute Coronary Syndrome | 2 | 2014 | 254 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 68 | 0.140 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2019 | 25 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2016 | 235 | 0.140 |
Why?
|
| Monitoring, Intraoperative | 1 | 2019 | 47 | 0.140 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1567 | 0.140 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2016 | 117 | 0.140 |
Why?
|
| Public Health | 1 | 2020 | 188 | 0.140 |
Why?
|
| Weight Loss | 2 | 2011 | 275 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2019 | 138 | 0.140 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2018 | 102 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2021 | 400 | 0.140 |
Why?
|
| Cystatin C | 1 | 2018 | 9 | 0.140 |
Why?
|
| Mortality | 1 | 2019 | 162 | 0.140 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 63 | 0.140 |
Why?
|
| Cunninghamella | 1 | 2018 | 1 | 0.140 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2018 | 22 | 0.140 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 5 | 0.140 |
Why?
|
| Mucormycosis | 1 | 2018 | 9 | 0.140 |
Why?
|
| Surgeons | 1 | 2021 | 191 | 0.130 |
Why?
|
| Cardiotonic Agents | 1 | 2018 | 54 | 0.130 |
Why?
|
| Behavior Control | 1 | 2017 | 15 | 0.130 |
Why?
|
| Self-Control | 1 | 2017 | 10 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2019 | 209 | 0.130 |
Why?
|
| Binge-Eating Disorder | 1 | 2017 | 13 | 0.130 |
Why?
|
| Telemedicine | 1 | 2023 | 376 | 0.130 |
Why?
|
| Assisted Circulation | 1 | 2017 | 1 | 0.130 |
Why?
|
| Counterpulsation | 1 | 2017 | 2 | 0.130 |
Why?
|
| Extracorporeal Circulation | 1 | 2017 | 6 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 231 | 0.130 |
Why?
|
| Device Approval | 1 | 2017 | 13 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 309 | 0.130 |
Why?
|
| Feasibility Studies | 4 | 2025 | 593 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2018 | 801 | 0.130 |
Why?
|
| Prostheses and Implants | 1 | 2017 | 71 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 1116 | 0.130 |
Why?
|
| Smokers | 1 | 2017 | 117 | 0.120 |
Why?
|
| Cannula | 1 | 2016 | 23 | 0.120 |
Why?
|
| Young Adult | 5 | 2022 | 4855 | 0.120 |
Why?
|
| Liraglutide | 1 | 2016 | 8 | 0.120 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2016 | 10 | 0.120 |
Why?
|
| Thrombolytic Therapy | 2 | 2015 | 204 | 0.120 |
Why?
|
| Postoperative Care | 2 | 2016 | 125 | 0.120 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2016 | 30 | 0.120 |
Why?
|
| Heart Function Tests | 1 | 2016 | 16 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2016 | 33 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 179 | 0.120 |
Why?
|
| Neutrophils | 1 | 2019 | 396 | 0.110 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 213 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 746 | 0.110 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 33 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 2730 | 0.110 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2015 | 25 | 0.110 |
Why?
|
| Enoxaparin | 1 | 2015 | 19 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 78 | 0.110 |
Why?
|
| Hirudins | 1 | 2014 | 12 | 0.110 |
Why?
|
| Models, Organizational | 1 | 2015 | 93 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 106 | 0.110 |
Why?
|
| Thromboembolism | 1 | 2015 | 74 | 0.100 |
Why?
|
| Research Design | 1 | 2017 | 590 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 225 | 0.100 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2018 | 367 | 0.100 |
Why?
|
| Antigens, CD | 2 | 2015 | 344 | 0.100 |
Why?
|
| Patient Selection | 2 | 2014 | 484 | 0.100 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2017 | 226 | 0.100 |
Why?
|
| Heparin | 1 | 2014 | 120 | 0.100 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 230 | 0.100 |
Why?
|
| Shock | 1 | 2013 | 34 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2014 | 107 | 0.100 |
Why?
|
| Heart, Artificial | 1 | 2012 | 2 | 0.090 |
Why?
|
| Multiple Organ Failure | 1 | 2013 | 48 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 872 | 0.090 |
Why?
|
| Central Venous Pressure | 2 | 2025 | 14 | 0.090 |
Why?
|
| Cardiomyopathies | 2 | 2013 | 137 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 161 | 0.090 |
Why?
|
| Pleural Effusion | 1 | 2012 | 40 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 709 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 169 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 273 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 348 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 188 | 0.090 |
Why?
|
| Health Behavior | 1 | 2015 | 485 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 429 | 0.090 |
Why?
|
| Heart Valve Diseases | 1 | 2012 | 94 | 0.090 |
Why?
|
| Obesity | 2 | 2017 | 1277 | 0.080 |
Why?
|
| Ventricular Pressure | 1 | 2010 | 31 | 0.080 |
Why?
|
| Thoracotomy | 2 | 2021 | 47 | 0.080 |
Why?
|
| Cardiology | 1 | 2012 | 170 | 0.080 |
Why?
|
| Body Image | 1 | 2010 | 32 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2015 | 468 | 0.080 |
Why?
|
| Decision Making | 1 | 2014 | 429 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2012 | 222 | 0.080 |
Why?
|
| Jugular Veins | 1 | 2010 | 28 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 631 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 770 | 0.080 |
Why?
|
| Weight Gain | 1 | 2010 | 165 | 0.070 |
Why?
|
| Patient Compliance | 2 | 2015 | 370 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 326 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 733 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 809 | 0.070 |
Why?
|
| Motivation | 1 | 2010 | 298 | 0.070 |
Why?
|
| Diet | 1 | 2011 | 536 | 0.070 |
Why?
|
| Plasmapheresis | 2 | 2019 | 17 | 0.060 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 34 | 0.060 |
Why?
|
| HLA Antigens | 2 | 2019 | 62 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2007 | 16 | 0.060 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2007 | 56 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2007 | 68 | 0.060 |
Why?
|
| Robotics | 1 | 2007 | 86 | 0.060 |
Why?
|
| Disease Progression | 2 | 2025 | 1227 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2006 | 175 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2025 | 78 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 372 | 0.050 |
Why?
|
| Hemofiltration | 1 | 2024 | 17 | 0.050 |
Why?
|
| Exercise | 1 | 2011 | 970 | 0.050 |
Why?
|
| Adolescent | 4 | 2022 | 6350 | 0.050 |
Why?
|
| Cachexia | 1 | 2023 | 13 | 0.050 |
Why?
|
| Computers, Handheld | 1 | 2023 | 37 | 0.050 |
Why?
|
| Uric Acid | 1 | 2023 | 47 | 0.050 |
Why?
|
| Telephone | 1 | 2023 | 123 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2022 | 142 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 71 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2023 | 162 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 76 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 88 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 161 | 0.040 |
Why?
|
| Body Composition | 1 | 2022 | 155 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2022 | 167 | 0.040 |
Why?
|
| Sternotomy | 1 | 2021 | 12 | 0.040 |
Why?
|
| Echocardiography | 2 | 2015 | 513 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 279 | 0.040 |
Why?
|
| Life History Traits | 1 | 2020 | 2 | 0.040 |
Why?
|
| Career Mobility | 1 | 2021 | 63 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 286 | 0.040 |
Why?
|
| Professional Competence | 1 | 2021 | 91 | 0.040 |
Why?
|
| Behavioral Medicine | 1 | 2020 | 37 | 0.040 |
Why?
|
| Comorbidity | 2 | 2014 | 1120 | 0.040 |
Why?
|
| Health Status | 1 | 2023 | 448 | 0.040 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 86 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2022 | 535 | 0.040 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2019 | 5 | 0.040 |
Why?
|
| Body Weight | 2 | 2011 | 377 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2019 | 32 | 0.040 |
Why?
|
| Pulsatile Flow | 1 | 2019 | 10 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 2019 | 25 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2019 | 59 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2018 | 16 | 0.040 |
Why?
|
| Rituximab | 1 | 2019 | 89 | 0.040 |
Why?
|
| Child | 3 | 2015 | 4634 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 888 | 0.030 |
Why?
|
| Muscle Cells | 1 | 2018 | 28 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 29 | 0.030 |
Why?
|
| Lung Diseases, Fungal | 1 | 2018 | 34 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2006 | 1163 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2018 | 122 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 101 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2018 | 125 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 104 | 0.030 |
Why?
|
| Myocarditis | 1 | 2018 | 68 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 245 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 788 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1592 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2016 | 301 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 994 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1453 | 0.030 |
Why?
|
| Health Promotion | 1 | 2020 | 523 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 211 | 0.030 |
Why?
|
| Valsalva Maneuver | 1 | 2015 | 11 | 0.030 |
Why?
|
| Photopheresis | 1 | 2015 | 1 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2015 | 2 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 20 | 0.030 |
Why?
|
| Splenectomy | 1 | 2015 | 39 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 2789 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 294 | 0.030 |
Why?
|
| Systole | 1 | 2014 | 109 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 757 | 0.030 |
Why?
|
| Complement System Proteins | 1 | 2015 | 110 | 0.030 |
Why?
|
| Uncertainty | 1 | 2014 | 40 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 374 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2015 | 292 | 0.030 |
Why?
|
| Cognition | 1 | 2017 | 511 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2014 | 133 | 0.020 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 27 | 0.020 |
Why?
|
| Self Care | 1 | 2015 | 218 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2013 | 88 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 381 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2014 | 212 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 741 | 0.020 |
Why?
|
| Transcriptome | 1 | 2016 | 405 | 0.020 |
Why?
|
| Myocardium | 1 | 2015 | 302 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2013 | 78 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2015 | 535 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 1273 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 405 | 0.020 |
Why?
|
| Graft Survival | 1 | 2013 | 300 | 0.020 |
Why?
|
| Patient Participation | 1 | 2014 | 239 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2013 | 230 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 309 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 2011 | 44 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 558 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 931 | 0.020 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2010 | 10 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 160 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 664 | 0.020 |
Why?
|
| Diet, Reducing | 1 | 2010 | 25 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2011 | 181 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 491 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1144 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 384 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1634 | 0.020 |
Why?
|
| Macrophages | 1 | 2015 | 1041 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2013 | 521 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3501 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 432 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2010 | 442 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2011 | 879 | 0.020 |
Why?
|
| Illinois | 1 | 2006 | 13 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 1715 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2006 | 288 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2006 | 152 | 0.010 |
Why?
|
| Palliative Care | 1 | 2007 | 250 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 805 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 11174 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2006 | 1437 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 1711 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 2076 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2006 | 725 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 21467 | 0.010 |
Why?
|